Christina Annette Herrera1,2, Tracy A Manuck1,2,3, Gregory J Stoddard4, Michael W Varner1,2, Sean Esplin1,2, Erin A S Clark1,2, Robert M Silver1,2, Alexandra G Eller1,2. 1. a Department of Obstetrics and Gynecology , University of Utah , Salt Lake City , UT , USA. 2. b Intermountain Healthcare Division of Maternal Fetal Medicine , Salt Lake City , UT , USA. 3. c Department of Obstetrics and Gynecology , University of North Carolina , Chapel Hill , NC , USA. 4. d Department of Internal Medicine , University of Utah , Salt Lake City , UT , USA.
Abstract
OBJECTIVE: The objective of this study is to examine perinatal outcomes associated with cholestasis of pregnancy according to bile acid level and antenatal testing practice. STUDY DESIGN: Retrospective cohort study of women with symptoms and bile acid testing from 2005 to 2014. Women were stratified by bile acid level: no cholestasis (<10 μmol/L), mild (10-39 μmol/L), moderate (40-99 μmol/L), and severe (≥100 μmol/L). The primary outcome was composite neonatal morbidity (hypoxic ischemic encephalopathy, severe intraventricular hemorrhage, bronchopulmonary dysplasia, necrotizing enterocolitis, or death). RESULTS: 785 women were included; 487 had cholestasis (347 mild, 108 moderate, 32 severe) and 298 did not. After controlling for gestational age (GA), severe cholestasis was associated with the composite neonatal outcome (aRR 5.6, 95% CI 1.3-23.5) and meconium-stained fluid (aRR 4.82, 95%CI 1.6-14.2). Bile acid levels were not correlated with the frequency of testing (p = .50). Women who underwent twice weekly testing were delivered earlier (p = .016) than women tested less frequently, but the difference in GA was ≤4 d. Abnormal testing prompting delivery was uncommon. Among women with cholestasis, there were three stillbirths. One of these women was undergoing antenatal testing, which was normal 1 d prior to the fetal demise. CONCLUSION: Severe cholestasis is associated with neonatal morbidity which antenatal testing may not predict.
OBJECTIVE: The objective of this study is to examine perinatal outcomes associated with cholestasis of pregnancy according to bile acid level and antenatal testing practice. STUDY DESIGN: Retrospective cohort study of women with symptoms and bile acid testing from 2005 to 2014. Women were stratified by bile acid level: no cholestasis (<10 μmol/L), mild (10-39 μmol/L), moderate (40-99 μmol/L), and severe (≥100 μmol/L). The primary outcome was composite neonatal morbidity (hypoxic ischemicencephalopathy, severe intraventricular hemorrhage, bronchopulmonary dysplasia, necrotizing enterocolitis, or death). RESULTS: 785 women were included; 487 had cholestasis (347 mild, 108 moderate, 32 severe) and 298 did not. After controlling for gestational age (GA), severe cholestasis was associated with the composite neonatal outcome (aRR 5.6, 95% CI 1.3-23.5) and meconium-stained fluid (aRR 4.82, 95%CI 1.6-14.2). Bile acid levels were not correlated with the frequency of testing (p = .50). Women who underwent twice weekly testing were delivered earlier (p = .016) than women tested less frequently, but the difference in GA was ≤4 d. Abnormal testing prompting delivery was uncommon. Among women with cholestasis, there were three stillbirths. One of these women was undergoing antenatal testing, which was normal 1 d prior to the fetal demise. CONCLUSION: Severe cholestasis is associated with neonatal morbidity which antenatal testing may not predict.
Entities:
Keywords:
Cholestasis; bile acids; perinatal outcomes; stillbirth
Authors: Caroline Ovadia; Paul T Seed; Alexandros Sklavounos; Victoria Geenes; Chiara Di Ilio; Jenny Chambers; Katherine Kohari; Yannick Bacq; Nuray Bozkurt; Romana Brun-Furrer; Laura Bull; Maria C Estiú; Monika Grymowicz; Berrin Gunaydin; William M Hague; Christian Haslinger; Yayi Hu; Tetsuya Kawakita; Ayse G Kebapcilar; Levent Kebapcilar; Jūratė Kondrackienė; Maria P H Koster; Aneta Kowalska-Kańka; Limas Kupčinskas; Richard H Lee; Anna Locatelli; Rocio I R Macias; Hanns-Ulrich Marschall; Martijn A Oudijk; Yael Raz; Eli Rimon; Dan Shan; Yong Shao; Rachel Tribe; Valeria Tripodi; Cigdem Yayla Abide; Ilter Yenidede; Jim G Thornton; Lucy C Chappell; Catherine Williamson Journal: Lancet Date: 2019-02-14 Impact factor: 202.731
Authors: Caroline Ovadia; Jenna Sajous; Paul T Seed; Kajol Patel; Nicholas J Williamson; George Attilakos; Francesco Azzaroli; Yannick Bacq; Linoy Batsry; Kelsey Broom; Romana Brun-Furrer; Laura Bull; Jenny Chambers; Yue Cui; Min Ding; Peter H Dixon; Maria C Estiú; Fergus W Gardiner; Victoria Geenes; Monika Grymowicz; Berrin Günaydin; William M Hague; Christian Haslinger; Yayi Hu; Ugo Indraccolo; Alexander Juusela; Stefan C Kane; Ayse Kebapcilar; Levent Kebapcilar; Katherine Kohari; Jūratė Kondrackienė; Maria P H Koster; Richard H Lee; Xiaohua Liu; Anna Locatelli; Rocio I R Macias; Riza Madazli; Agata Majewska; Kasia Maksym; Jessica A Marathe; Adam Morton; Martijn A Oudijk; Deniz Öztekin; Michael J Peek; Andrew H Shennan; Rachel M Tribe; Valeria Tripodi; Naciye Türk Özterlemez; Tharni Vasavan; L F Audris Wong; Yoav Yinon; Qianwen Zhang; Keren Zloto; Hanns-Ulrich Marschall; Jim Thornton; Lucy C Chappell; Catherine Williamson Journal: Lancet Gastroenterol Hepatol Date: 2021-04-27
Authors: Lucy C Chappell; Jennifer L Bell; Anne Smith; Louise Linsell; Edmund Juszczak; Peter H Dixon; Jenny Chambers; Rachael Hunter; Jon Dorling; Catherine Williamson; Jim G Thornton Journal: Lancet Date: 2019-08-01 Impact factor: 79.321